News
NHS makes fresh uptake appeal as five million women not up to date with cervical screening
Women are being urged to come forward for cervical screening as new figures show more than five million are not up to date with their routine check-ups.
The NHS invites women for screening every three to five years depending on their age, or more frequently if the high-risk human papillomavirus (HPV) is detected, with the programme saving thousands of lives annually.
The NHS Cervical Screening Programme, England 2023-2024 annual report found that 68.8 per cent of 25 to 64-year-olds were screened within the recommended period of time, compared to 68.7 per cent the previous year.
Coverage was higher for 50 to 64-year-olds at 74.3 per cent compared with 25 to 49-year-olds at 66.1 per cent.
In 2023-24, everyone who was due a test – a total of 5.12 million individuals aged 25 to 64 in England – was invited to book an appointment, and 3.25 million were tested during the year.
Last year, the NHS pledged to eliminate cervical cancer by 2040 by making it as easy as possible for people to get the lifesaving HPV vaccination and encouraging more women and people with a cervix to come forward for their cervical screening.
Earlier this month, the NHS set out reforms to fully digitise screening – by announcing the rollout of a new “ping and book” service that will send alerts to phones to remind women they are due or overdue an appointment.
The plans will begin with invitations for breast screening being sent directly through the NHS App, and be expanded to include cervical screening in Spring 2025.
NHS cervical screening helps prevent cervical cancer by using a highly effective test to check for HPV, which is found in over 99 per cent of all cervical cancers and which may cause abnormal cells to develop in the cervix. These abnormal cells can, over time, turn into cancer if left untreated.
Women who are due a cervical screening appointment will receive invitation letters by post when it’s time to book. Appointments can be booked through GP practices and some sexual health clinics also offer the service. A
nyone who has previously received an invitation and been unable to attend shouldn’t wait for another invitation – you can still book a cervical screening appointment even if invited weeks, months or years ago.
Sue Mann, NHS England’s National Clinical Director for Women’s Health, said: “We have set ourselves an ambitious target of eliminating cervical cancer by 2040 – a commitment shared by only a few countries worldwide.
“In order to achieve this, we are working hard to ensure that everyone who’s eligible has access to HPV vaccination and cervical screening appointments, and that they are suitably informed on how to book and what to expect at an appointment.
“If we are to make real inroads into eradicating cervical cancer, it’s essential that everyone who is invited for screening comes forward when invited.
“If you have previously missed your appointment, do not hesitate to reach out to your GP practice or sexual health clinic to schedule a new one. Taking this proactive step could potentially save your life.”
Sophia Lowes, Senior Health Information Manager at Cancer Research UK, said: “Cervical screening saves thousands of lives every year in the UK.
“It’s for people without symptoms and helps to prevent cervical cancer from developing in the first place.
“Cancer Research UK encourages everyone who receives an invitation to take part.
“Some people may have found cervical screening uncomfortable in the past or have experienced other barriers to taking part.
“But there are things you can ask for to help you feel more comfortable, such as asking for a nurse of a specific gender or asking for a smaller speculum – the tool that nurses use to look at your cervix.
“You can also ask for a longer appointment so you can talk through any concerns with the nurse on what adjustments you might need.
“On top of this, the NHS in England is taking steps to make it easier to take part in cervical screening, such as letting you book your appointment through the NHS App.
“In the future, innovations like HPV self-sample kits, which allow people to collect a sample for testing themselves, could help more people take part.
“We’re looking forward to seeing the impact these new initiatives could have.”
England is among the first countries in the world to set the elimination ambition for cervical cancer within the next two decades.
The World Health Organization considers cervical cancer to be eliminated as a public health problem when there is an incidence rate lower than four per 100,000 women.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






